Preoperative radiotherapy improves outcome in rectal cancer

October 18, 2001

N.B. Please note that if you are outside North America the embargo for Lancet press material is 0001 hours UK time Friday 19th October 2001.

Preoperative radiotherapy reduces risk of local recurrence and death from rectal cancer, conclude authors of a systematic overview published in this week's issue of The Lancet.

There are different opinions about when it is best to give radiotherapy for rectal cancer. In Scandinavia, the Netherlands, and some other European countries, radiotherapy is usually given before an operation to remove the cancer, whereas in the UK and North America, radiotherapy is usually given after the operation. An analysis of data from 8507 patients in 22 trials of radiotherapy treatment before or after surgery for cancer of the rectum (lower bowel) by the Colorectal Cancer Collaborative Group suggests that radiotherapy before surgery is preferable.

"We found there were about half as many local recurrences in those who had preoperative radiotherapy compared to those who had surgery alone. In those who had postoperative radiotherapy, local recurrences were reduced by a third." said Richard Gray from the University of Birmingham, UK, one of the organisers of the study. "We also found that fewer patients who had preoperative radiotherapy died from rectal cancer than did those who had surgery alone (45% vs 50%) but early deaths from other causes increased."

In an accompanying Commentary (p1285), Bruce D Minsky, from The Sloan Kettering Cancer Centre in New York, USA, cautions that the results "... give support to adjuvant radiotherapy for rectal cancer. The uncertainties are the timing of the radiotherapy, the regimens...and the value of concurrent chemotherapy."
-end-
Contacts: Professor Richard Gray, University of Birmingham Clinical Trials Unit, Park Grange, 1 Somerset Road, Edgbaston, Birmingham B15 2RR, UK, T) +44 (0)121 687 2310; Mobile) +44 (0)7768 696407; F) +44 (0) 121 687 2313. E )r.gray@bham.ac.uk

Dr Bruce D Minsky, Department of Radiation Oncology, Sloan Kettering Cancer Centre, New York, USA. E) minskyb@mmkee.org

Lancet

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.